Dihydropyrimidinase Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD) . DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.
Synonyms
DHP; DHPase; Dihydropyrimidinase; Dihydropyrimidine amidohydrolase; Dpys; DPYS_HUMAN; Hydantoinase.
Gene ID
1807
Cellular Locus
Cytoplasm, Secreted, Extracellular matrix
Host
Rabbit
Immunogen
121-220/519
Target
Dihydropyrimidinase
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human DHP/Dihydropyrimidinase
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
1807
Predicted Cross Reactivity
Human, Mouse, Rat, Dog, Cow, Sheep, Chicken
More Discoveries
Explore Other Products
Browse additional items from our catalog